Compare LARK & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LARK | BDSX |
|---|---|---|
| Founded | 1885 | 2005 |
| Country | United States | United States |
| Employees | 283 | N/A |
| Industry | Major Banks | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.7M | 107.5M |
| IPO Year | 2001 | 2020 |
| Metric | LARK | BDSX |
|---|---|---|
| Price | $26.68 | $11.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 3.2K | ★ 52.8K |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 35.84 | N/A |
| EPS | ★ 3.07 | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | N/A | $25.26 |
| Revenue Next Year | N/A | $19.15 |
| P/E Ratio | $8.69 | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $23.43 | $0.25 |
| 52 Week High | $30.85 | $20.21 |
| Indicator | LARK | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 54.83 | 40.65 |
| Support Level | $27.01 | $6.00 |
| Resistance Level | $28.93 | $11.57 |
| Average True Range (ATR) | 0.64 | 1.09 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 45.69 | 37.00 |
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and Southwest Kansas.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.